Last reviewed · How we verify
Gleevec
Gleevec is a Small molecule drug developed by M.D. Anderson Cancer Center. It is currently FDA-approved for Blastic phase chronic myeloid leukemia, Chronic Myelocytic Leukemia Accelerated Phase, Chronic eosinophilic leukemia. Also known as: Imatinib Mesylate, STI-571, Imatinib, NSC-716051.
At a glance
| Generic name | Gleevec |
|---|---|
| Also known as | Imatinib Mesylate, STI-571, Imatinib, NSC-716051, imatinib mesylate |
| Sponsor | M.D. Anderson Cancer Center |
| Target | Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, ATP-binding cassette sub-family G member 2, ATP-dependent RNA helicase DDX3X |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Blastic phase chronic myeloid leukemia
- Chronic Myelocytic Leukemia Accelerated Phase
- Chronic eosinophilic leukemia
- Chronic phase chronic myeloid leukemia
- Dermatofibrosarcoma protuberans
- Gastrointestinal stromal tumor
- Idiopathic hypereosinophilic syndrome
- Myelodysplastic/myeloproliferative diseases with re-arrangements of the gene for platelet-derived growth factor receptor (PDGFR)
- Philadelphia Chromosome Positive Chronic Myelocytic Leukemia
- Philadelphia chromosome-positive acute lymphoblastic leukemia
- Systemic mast cell disease
Common side effects
- Edema
- Nausea
- Vomiting
- Muscle cramps
- Musculoskeletal pain
- Diarrhea
- Rash
- Fatigue
- Abdominal pain
- Neutropenia
- Thrombocytopenia
- Cytopenias
Serious adverse events
- Acute liver failure
- Grade 3 or 4 neutropenia
- Grade 3 or 4 thrombocytopenia
- Severe hepatotoxicity
- Pulmonary edema
- Pleural effusion
- Ascites
Key clinical trials
- A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia (PHASE3)
- Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML (PHASE2)
- Trial of Imatinib for Hospitalized Adults With COVID-19 (PHASE3)
- Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor (PHASE1)
- Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase (PHASE2)
- A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy (PHASE3)
- Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia (PHASE2)
- A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gleevec CI brief — competitive landscape report
- Gleevec updates RSS · CI watch RSS
- M.D. Anderson Cancer Center portfolio CI
Frequently asked questions about Gleevec
What is Gleevec?
Gleevec is a Small molecule drug developed by M.D. Anderson Cancer Center, indicated for Blastic phase chronic myeloid leukemia, Chronic Myelocytic Leukemia Accelerated Phase, Chronic eosinophilic leukemia.
What is Gleevec used for?
Gleevec is indicated for Blastic phase chronic myeloid leukemia, Chronic Myelocytic Leukemia Accelerated Phase, Chronic eosinophilic leukemia, Chronic phase chronic myeloid leukemia, Dermatofibrosarcoma protuberans.
Who makes Gleevec?
Gleevec is developed and marketed by M.D. Anderson Cancer Center (see full M.D. Anderson Cancer Center pipeline at /company/m-d-anderson-cancer-center).
Is Gleevec also known as anything else?
Gleevec is also known as Imatinib Mesylate, STI-571, Imatinib, NSC-716051, imatinib mesylate.
What development phase is Gleevec in?
Gleevec is FDA-approved (marketed).
What are the side effects of Gleevec?
Common side effects of Gleevec include Edema, Nausea, Vomiting, Muscle cramps, Musculoskeletal pain, Diarrhea. Serious adverse events: Acute liver failure, Grade 3 or 4 neutropenia, Grade 3 or 4 thrombocytopenia, Severe hepatotoxicity.
What does Gleevec target?
Gleevec targets Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, ATP-binding cassette sub-family G member 2, ATP-dependent RNA helicase DDX3X.
Related
- Target: All drugs targeting Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, ATP-binding cassette sub-family G member 2, ATP-dependent RNA helicase DDX3X
- Manufacturer: M.D. Anderson Cancer Center — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Blastic phase chronic myeloid leukemia
- Indication: Drugs for Chronic Myelocytic Leukemia Accelerated Phase
- Indication: Drugs for Chronic eosinophilic leukemia
- Also known as: Imatinib Mesylate, STI-571, Imatinib, NSC-716051, imatinib mesylate
- Compare: Gleevec vs similar drugs
- Pricing: Gleevec cost, discount & access